Sterling Investment Counsel LLC Acquires 4,167 Shares of AbbVie Inc. $ABBV

Sterling Investment Counsel LLC boosted its stake in shares of AbbVie Inc. (NYSE:ABBV) by 128.4% during the third quarter, Holdings Channel reports. The fund owned 7,412 shares of the company’s stock after acquiring an additional 4,167 shares during the period. Sterling Investment Counsel LLC’s holdings in AbbVie were worth $1,716,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Ellenbecker Investment Group increased its holdings in shares of AbbVie by 0.8% in the third quarter. Ellenbecker Investment Group now owns 5,334 shares of the company’s stock valued at $1,235,000 after purchasing an additional 44 shares in the last quarter. Security National Bank of Sioux City Iowa IA boosted its position in AbbVie by 0.3% in the 3rd quarter. Security National Bank of Sioux City Iowa IA now owns 15,382 shares of the company’s stock valued at $3,562,000 after buying an additional 45 shares during the last quarter. Matthew Goff Investment Advisor LLC increased its stake in shares of AbbVie by 0.3% in the 3rd quarter. Matthew Goff Investment Advisor LLC now owns 17,561 shares of the company’s stock valued at $4,066,000 after buying an additional 45 shares during the period. Willner & Heller LLC increased its stake in shares of AbbVie by 0.6% in the 3rd quarter. Willner & Heller LLC now owns 7,596 shares of the company’s stock valued at $1,759,000 after buying an additional 46 shares during the period. Finally, Hobart Private Capital LLC lifted its stake in shares of AbbVie by 4.4% during the third quarter. Hobart Private Capital LLC now owns 1,127 shares of the company’s stock valued at $261,000 after acquiring an additional 48 shares during the period. 70.23% of the stock is owned by institutional investors.

AbbVie Stock Performance

Shares of NYSE:ABBV opened at $229.26 on Friday. AbbVie Inc. has a 52 week low of $164.39 and a 52 week high of $244.81. The company has a market capitalization of $405.19 billion, a PE ratio of 173.68, a PEG ratio of 0.96 and a beta of 0.36. The company has a 50 day moving average price of $226.69 and a two-hundred day moving average price of $213.74.

AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, topping analysts’ consensus estimates of $1.77 by $0.09. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The company had revenue of $15.78 billion for the quarter, compared to analysts’ expectations of $15.58 billion. During the same period last year, the firm posted $3.00 earnings per share. The business’s quarterly revenue was up 9.1% compared to the same quarter last year. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. On average, sell-side analysts forecast that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be paid a $1.73 dividend. The ex-dividend date of this dividend is Friday, January 16th. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 dividend on an annualized basis and a yield of 3.0%. AbbVie’s payout ratio is presently 496.97%.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the company. Erste Group Bank lowered AbbVie from a “buy” rating to a “hold” rating in a research report on Tuesday, October 14th. UBS Group lifted their price target on shares of AbbVie from $195.00 to $220.00 and gave the stock a “neutral” rating in a research report on Friday, November 7th. Berenberg Bank upgraded shares of AbbVie from a “hold” rating to a “buy” rating and increased their price objective for the company from $170.00 to $270.00 in a report on Wednesday, September 17th. DZ Bank lowered shares of AbbVie from a “buy” rating to a “hold” rating and set a $237.00 target price for the company. in a report on Tuesday, November 4th. Finally, Cantor Fitzgerald set a $250.00 price target on AbbVie and gave the company an “overweight” rating in a research note on Thursday, October 9th. Three equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and eight have issued a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $245.84.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.